Drug Induced Liver Disease Role of the Pathologist. Disclosure. DILI can never be excluded. Romil Saxena, MD. Dr. Saxena has nothing to Disclose

Similar documents
Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

British Liver Transplant Group Pathology meeting September Leeds cases

HHS Public Access Author manuscript Hepatology. Author manuscript; available in PMC 2017 March 01.

PITFALLS IN THE DIAGNOSIS OF MEDICAL LIVER DISEASE WITH TWO CONCURRENT ETIOLOGIES I HAVE NOTHING TO DISCLOSE CURRENT ISSUES IN ANATOMIC PATHOLOGY 2017

Diagnostic evaluation of suspected Drug-Induced Liver Injury

LIVER SPECIALTY CONFERENCE USCAP Maha Guindi, M.D. Clinical Professor of Pathology Cedars-Sinai Medical Center Los Angeles, CA

DILI PATHOLOGY. PHILIP KAYE November 2017 BSG Pathology Winter Meeting

Disclosures Drug-induced Acute Liver Failure

Drug-induced liver injury

AMR in Liver Transplantation: Incidence

Approach to the Patient with Liver Disease

Case n 1 ( B 92 / 4208 ) Case n 2 ( B 00 / 8249 ) Case n 3 ( B 98 / 8352 )

Basic patterns of liver damage what information can a liver biopsy provide and what clinical information does the pathologist need?

Slide 7 demonstrates acute pericholangitisis with neutrophils around proliferating bile ducts.

Abnormal Liver Chemistries. Lauren Myers, MMsc. PA-C Oregon Health and Science University

HIV/AIDS and the Liver : interlinking challenges

Noncalculous Biliary Disease Dean Abramson, M.D. Gastroenterologists, P.C. Cedar Rapids. Cholestasis

Autoimmune Hepatitis in Clinical Practice

Chronic Liver Disease after Acute Hepatocellular DILI

Primary Sclerosing Cholangitis and Cholestatic liver diseases. Ahsan M Bhatti MD, FACP Bhatti Gastroenterology Consultants

Fat, ballooning, plasma cells and a +ANA. Yikes! USCAP 2016 Evening Specialty Conference Cynthia Guy

A Review of Liver Function Tests. James Gray Gastroenterology Vancouver

EVALUATION OF ABNORMAL LIVER TESTS

I have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES

Steatosis/Steatohepatitis

Autoimmune Liver Diseases

Linda Ferrell, MD Distinguished Professor Vice Chair Director of Surgical Pathology Dept of Pathology

Biliary tract diseases of the liver

Drug Induced Liver Injury (DILI)

Autoimmune Hepatobiliary Diseases PROF. DR. SABEHA ALBAYATI CABM,FRCP

How to Approach a Medical Liver Biopsy. 9 th Bryan Warren School of Pathology Pancreatic and Liver Pathology. Sarajevo, 6 th -7 th November 2015

Chronic Biliary Disease. Dr Susan Davies & Dr Bill Griffiths

Overview of PSC Making the Diagnosis

Acute and Chronic Hepatitis John Hart, M.D. University of Chicago Medical Center

Acute Hepatitis in a Patient with NASH and Elevation of CMV-IgM

Good afternoon. Thanks, John, very much for the invitation to be here today. I am delighted to discuss elevated transaminases in the setting of heart

Extrahepatic Biliary Obstruction. Ductal Diseases: Stones Tumors. Acute Injury: Viral Hepatitis Toxin (APAP/Etoh) Reye s Shock.

VIRAL HEPATITIS. Definitions. Acute Liver Disease (Hepatitis A &E, Alcoholic hepatitis, DILI and ALF) Acute Viral Hepatitis Symptoms

4/27/2018. Disclosures LIVER FUNCTION TESTS LIVER FUNCTION TESTS LIVER FUNCTION TESTS APPROACH TO THE PATIENT WITH ABNORMAL LIVER TESTS

MANAGEMENT OF DILI in TB/HIV coinfected patients. Chimoio 31 August 2017 by Dr Ndiviwe Mphothulo

DRUG INDUCED LIVER INJURY DIPENDRA PARAJULI 02/02/2006. University of Louisville

What Is Cirrhosis? CIRRHOSIS. Cirrhosis occurs when the liver is. by chronic conditions and diseases. permanently scarred or injured

Drug-induced Biliary Disease

Hepatic sinusoidal obstruction syndrome due to herbal ingestion in South African children - An 8 year review

Nottingham Patterns of liver fibrosis and their clinical significance

1. Based on A.S. s labs and presentation, what type of liver injury would you classify her as experiencing?

AASLD: Boston Rob Goldin

ACP-BSG meeting The liver in systemic inflammatory disorders. Dr Adrian C Bateman Southampton University Hospitals NHS Trust

Liver Transplantation

Do Histological Features Inform DILI mechanisms?

HOW TO DEAL WITH THOSE ABNORMAL LIVER ENZYMES David C. Twedt DVM, DACVIM Colorado State University Fort Collins, CO

Liver Transplant Pathology a general view

Circulation T. Manchester July 5 th 2006

This is your liver. Overview. Functions of the Liver 3/9/2015. This is your liver on Drugs. Drugs and the Liver Drug Induced Liver Injury (DILI)

Therapies for DILI: NAC, Steroids or NRF-2 activators?

Topic review - A patient with impaired liver function. Dr. Karen Hin Kwan Luk 18/1/2018

Drug-, herb- and dietary supplement-induced liver injury

Supplemental Tables. Parasitic Schistosomiasis increase < 1. Genetic Hemochromatosis increase < 1. autoimmune Autoimmune hepatitis (AIH) increase < 1

Drug Induced Liver Injury: A Clinical Perspective. Robert J. Fontana, MD

06 June 2017 DILI Conference XVII FDA/AASLD/Critical Path Institute

Prof. Dr. Hedef Dhafir El-Yassin. Prof. Dr. El-Yassin

TB Case Management Hepatitis

Drug- induced Liver Injury. Guruprasad P. Aithal

Cirrhosis. A Chronic Liver Problem

Hangzhou, 15 March Ulrich Beuers Department of Gastroenterology and Hepatology Academic Medical Center University of Amsterdam

Liver Disease That Presents with Jaundice (PBC, Alcohol and Drugs): Diagnosis and Patient Management. Emma Pham, PA-C

Overview of PSC Jayant A. Talwalkar, MD, MPH Associate Professor of Medicine Mayo Clinic Rochester, MN

Chronic Cholestatic Liver Diseases

Chronic Hepatitis C. Risk Factors

Autoimmune Liver Disease

What to do with abnormal LFTs? Andrew M Smith Hepatobiliary Surgeon

Key Points: Autoimmune Liver Disease: Update for Pathologists from the Hepatologist s Perspective. Jenny Heathcote, MD. University of Toronto

ACCME/Disclosures. The Overlap Syndromes: Do They Exist? Key Points and Questions 4/6/2016. Hans Popper Hepatopathology Society

Autoimmune hepatitis

So, this is a group of patients that were treated with an anti-inflammatory drug in development within Eli Lilly. The name of the compound was an

PBC/AIH variant/ overlap syndrome vs PBC with hepatitic features?

Management of acute alcoholic hepatitis

Non-infectious hepatic complications in patients with GVHD

Approach to the Patient with Abnormal Liver Enzymes

Histology. The pathology of the. bile ducts. pancreas. liver. The lecture in summary. Vt-2006

Autoimmune Hepatitis. Dr. Stefania Casu Hepatology, UVCM, Inselspital Bern. November 14th, 2018

Dhanpat Jain Yale University School of Medicine, New Haven, CT

A Systematic Approach to Medical Liver Disease

Steatotic liver disease

GASTROENTEROLOGY ESSENTIALS

Biliary Atresia. Karen F. Murray, MD Professor of Pediatrics Director, Hepatobiliary Program Seattle Children s

What s new in liver transplantation? Romil Saxena, MD, FRCPath (UK) Indiana University School of Medicine, Indianapolis

Pediatric Primary Sclerosing Cholangitis and Potential Therapies

Pretreatment Evaluation

BRIDGE THE GAP A Human Pathways Approach to Disease Research

Primary Sclerosing Cholangitis Medical Management

Should There Be a Standard of Care (SOC) for Drug-Induced Liver Injury (DILI)? Leonard B Seeff, MD

IN THE NAME OF GOD. D r. MANIJE DEZFULI AZAD UNIVERCITY OF TEHRAN BOOALI HOSPITAL INFECTIOUS DISEASES SPECIALIST

Prolonged Neonatal Jaundice

MDR TB/HIV INTEGRATION MDR TB WORKSHOP 18 SEPTEMBER 2015

Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.

Primary Biliary Cholangitis

Updates from the AASLD

Chronic liver allograft dysfunction. An unsolved problem

PROGRAMME AT A GLANCE

Transcription:

Drug Induced Liver Disease Role of the Pathologist Romil Saxena, MD Disclosure Dr. Saxena has nothing to Disclose DILI can never be excluded #1 DILI has no specific pattern of injury it can mimic any and every other pattern #2 DILI is always in the differential diagnosis 1

Diagnosis of DILI Demonstrate association with the drug temporal relationship of symptoms to drug use resolution on drug removal (recurrence on rechallenge) Exclude other potential competing causes Diagnosis is challenging Drug history is not always clear Patient s ability as a historian Patient does not mention herbals (safe natural product, not a drug?!) Patient taking many meds (polypharmacy) No specific clinical pattern No specific biochemical pattern No specific diagnostic test Diagnosis is challenging Ever increasing use of medications; polypharmacy new therapeutic compounds for cancer and autoimmune diseases number and use of herbal compounds and nutritional supplements Propensity for injury and type of injury not known for newer agents CIOMS score Scores translated into categories of suspicion definite or highly probable (score 8) probable (score 6 8) possible (score 3 5) unlikely (score 1 2) excluded (score 0) Council for International Organizations of Medical Sciences (Geneva, Switzerland) 2

What is the role of a pathologist? Two questions Can we make a diagnosis on histology alone? Is this injury due to a drug? Which drug? Centrilobular necrosis with no inflammation Acetaminophen Ischemia Zone 3 necrosis 3

Cholestasis with no inflammation, cell damage or ductular reaction bland cholestasis Anabolic steroids very early obstruction Alcoholic steatohepatitis pattern with numerous well defined Mallory hyaline except they are periportal Amiodarone 4

Drug specific patterns Acetaminophen: Zone 3 necrosis Androgenic steroids: canalicular cholestasis Amiodarone: steatohepatitis Both questions answered: is this injury due to a drug? which drug? Cholestatic hepatitis Hardly ever seen outside context of DILI Amoxicillin clavalunate 10% of all DILI cases in various series second most common drug within DILIN with biopsies Floroquinolones Several other drugs 5

bland loss of bile ducts Hardly ever see outside the context of transplantation Liver transplantation rejection Bone marrow transplantation GVHD and DILI No consistent association with any drug Bland loss of bile ducts Diagnosis of duct loss 50% portal tracts without bile ducts (unpaired arterioles) with at least 10 portal tracts in the biopsy 90 95% of portal tracts contain pairs of arterioles and bile ducts a small number (7%) of portal tracts may have unpaired arterioles in normal livers Marked cholestasis ± inflammation Veno occlusive disease 6

Veno occlusive disease/ sinusoidal obstruction syndrome Hardly ever seen outside context of DILI Oxaliplatin Ablative therapies Azathioprine Jamaican bush tea (toxin) Patterns almost exclusive to DILI Cholestatic hepatitis Bland loss of bile ducts (outside context of transplantation) Veno occlusive disease Is this injury due to drug? most likely Which drug? not always possible 7

58 year old obese male, alcohol use Fatigue, abdominal pain, pale stools Bili 7 (direct 4.1), AP 589, ALT 82, AST 71, leucocytosis (14.9 but no eosinophilia) Negative viral and autoimmune markers No biliary dilatation 3 months earlier had been started on trazadone Bili went up to 17.2 when biopsy was done Drug stopped; 3 months later came down to 1.9 Trastuzumab emtansine (T DM1) antibody drug conjugate trastuzumab, a recombinant antiepidermal growth factor receptor 2 (HER2) monoclonal antibody thioether linker mertansine (DM1), a maytansinoid trastuzumab moiety binds to HER2 on tumor cell surfaces and on internalization, the DM1 moiety is released and binds to tubulin, thereby disrupting microtubule assembly/ disassembly dynamics, resulting in cell cycle arrest and cell death. General patterns (also seen with non DILI injury) Diagnosis requires temporal association of injury to drug intake exclusion of competing causes Both questions is injury due to drug which drug require clinical input (CPC) 8

Drugs with known general/non DILI patterns Oddball pattern that does not fit Is injury due to drug? requires temporal association and exclusion of other causes Which drug? narrow differential INH: submassive necrosis TNFα inhibitors, nitrofurantoin, α methyldopa: autoimmune hepatitis Tracey Bender 24 year old Ripped Fuel X (body building supplement containing ephedra) for 3 4 months (april july) followed by Lipo 6 (july august) 2 weeks later had jaundice Nausea, vomiting, headache, dark urine Bili 7.6, AP 316, ALT 177, AST 156 Viral, autoimmune markers negative MRCP negative Drugs discontinued : bili came down to 1.6 in a month and 4 months later was 0.9 9

Challenge of herbals and nutritional supplements Usage common and increasing Considered safe natural products Formulations non standardized Change over time in purity, potency and concentration Botanical products change with harvest conditions Often contain active drugs Establishing causality History not forthcoming (safe natural products) Taken over long periods of time Self perpetuating High degree of clinical suspicion History taking with direct questioning, specifically for supplements (health foods, herbals) Role of the surgical pathologist Drug Induced Liver Injury Network An NIH Initiative recognize and identify known patterns of drug injury confirm diagnosis when drug history known diagnose when drug history not known suspect drug (and alert) when injury pattern is odd and does not fit define pattern of injury of new agents 10

DILI What about eosinophils? HCV HBV 11

PBC SARCOID DILI can never be excluded Eosinophils are not specific or sensitive for DILI Present in hypersensitivity types of DILI reactions Useful for diagnosis of DILI in the appropriate context 12